- Home
- BMEA vs TDUP Comparison
BMEA vs TDUP Comparison
Compare BMEA & TDUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- TDUP
- Stock Information
- Founded
- BMEA 2017
- TDUP 2009
- Country
- BMEA United States
- TDUP United States
- Employees
- BMEA N/A
- TDUP N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- TDUP Catalog/Specialty Distribution
- Sector
- BMEA Health Care
- TDUP Consumer Discretionary
- Exchange
- BMEA Nasdaq
- TDUP Nasdaq
- Market Cap
- BMEA 65.8M
- TDUP 927.1M
- IPO Year
- BMEA 2021
- TDUP 2021
- Fundamental
- Price
- BMEA $1.94
- TDUP $7.16
- Analyst Decision
- BMEA Strong Buy
- TDUP Buy
- Analyst Count
- BMEA 10
- TDUP 3
- Target Price
- BMEA $22.30
- TDUP $7.25
- AVG Volume (30 Days)
- BMEA 2.2M
- TDUP 2.8M
- Earning Date
- BMEA 07-30-2025
- TDUP 08-04-2025
- Dividend Yield
- BMEA N/A
- TDUP N/A
- EPS Growth
- BMEA N/A
- TDUP N/A
- EPS
- BMEA N/A
- TDUP N/A
- Revenue
- BMEA N/A
- TDUP $266,789,000.00
- Revenue This Year
- BMEA N/A
- TDUP $12.30
- Revenue Next Year
- BMEA N/A
- TDUP $7.59
- P/E Ratio
- BMEA N/A
- TDUP N/A
- Revenue Growth
- BMEA N/A
- TDUP 7.96
- 52 Week Low
- BMEA $1.29
- TDUP $0.50
- 52 Week High
- BMEA $13.07
- TDUP $8.75
- Technical
- Relative Strength Index (RSI)
- BMEA 49.92
- TDUP 46.04
- Support Level
- BMEA $1.58
- TDUP $6.59
- Resistance Level
- BMEA $2.01
- TDUP $8.00
- Average True Range (ATR)
- BMEA 0.15
- TDUP 0.52
- MACD
- BMEA 0.01
- TDUP -0.18
- Stochastic Oscillator
- BMEA 80.00
- TDUP 23.22
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.